APIS Assay Technologies

Executive Summary

APIS Assay Technologies Ltd is a UK-based molecular diagnostics company leveraging its proprietary Clickmer® technology—chemically modified aptamers that serve as synthetic antibody analogues. Founded in 2014 and headquartered in Manchester, the company develops high-quality molecular assays, bioinformatics tools, and innovative services aimed at enabling faster, accurate prediction and prevention of disease. Clickmers offer advantages over traditional antibodies in terms of stability, cost, and production scalability, positioning APIS to address unmet needs in point-of-care and decentralized diagnostics. The company targets applications in infectious disease, oncology, and chronic disease management, with a focus on transforming diagnostic workflows through robust, multiplexed assays. APIS is well-positioned in the growing molecular diagnostics market, driven by demand for rapid, accessible testing. The company has been actively advancing its pipeline and forging strategic collaborations to commercialize its technology. While still private and early-stage, APIS has demonstrated proof-of-concept for its Clickmer platform and is pursuing regulatory approvals and partnerships to scale. Key near-term milestones include expanding its assay menu, securing clinical validation data, and raising additional capital to support commercialization. With a strong IP portfolio and a differentiated technology, APIS Assay Technologies represents a compelling opportunity in the diagnostics space.

Upcoming Catalysts (preview)

• Q2 2027Strategic partnership with a global diagnostics company for co-development of Clickmer-based assays60% success
• Q1 2027Completion of proof-of-concept study for a lead infectious disease assay85% success
• Q3 2026Series B funding round to support commercialization and regulatory submission70% success